Header Logo

Connection

Frederick Raal to Anticholesteremic Agents

Back to Details
This is a "connection" page, showing publications Frederick Raal has written about Anticholesteremic Agents.
Frederick Raal
Connection Strength
22,919
Anticholesteremic Agents
  1. Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial. Lancet Diabetes Endocrinol. 2025 Mar; 13(3):178-187.
    View in: PubMed
    Score: 0,870
  2. Ezetimibe in the management of homozygous familial hypercholesterolaemia. J Clin Lipidol. 2025 Mar-Apr; 19(2):320-326.
    View in: PubMed
    Score: 0,858
  3. Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies. Arterioscler Thromb Vasc Biol. 2024 May; 44(5):1156-1164.
    View in: PubMed
    Score: 0,821
  4. Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment. Eur J Prev Cardiol. 2024 Feb 15; 31(3):302-310.
    View in: PubMed
    Score: 0,815
  5. Coronary microcirculatory dysfunction in hypercholesterolemic patients with COVID-19: potential benefit from cholesterol-lowering treatment. Ann Med. 2023 12; 55(1):2199218.
    View in: PubMed
    Score: 0,803
  6. Modelling the potential long-term survival benefit of evinacumab treatment vs. standard of care in patients with homozygous familial hypercholesterolaemia. Eur J Prev Cardiol. 2023 11 30; 30(17):1874-1880.
    View in: PubMed
    Score: 0,803
  7. Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial. Circulation. 2024 01 30; 149(5):354-362.
    View in: PubMed
    Score: 0,796
  8. Novel therapies for familial hypercholesterolemia. Curr Opin Endocrinol Diabetes Obes. 2021 04 01; 28(2):188-195.
    View in: PubMed
    Score: 0,668
  9. New cholesterol targets for patients at high or very high cardiovascular risk and the indications for PCSK9 inhibitors. S Afr Med J. 2020 Oct 28; 110(11):13126.
    View in: PubMed
    Score: 0,648
  10. The therapeutic management of South African dyslipidaemic patients at very high cardiovascular risk (CARDIO TRACK): a cross-sectional study. Cardiovasc J Afr. 2020 Sep/Oct; 31(5):245-251.
    View in: PubMed
    Score: 0,641
  11. Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med. 2020 08 20; 383(8):711-720.
    View in: PubMed
    Score: 0,640
  12. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. J Am Coll Cardiol. 2020 02 18; 75(6):565-574.
    View in: PubMed
    Score: 0,618
  13. Long-term safety and efficacy of alirocumab in South African patients with heterozygous familial hypercholesterolaemia: the ODYSSEY Open-Label Extension study. Cardiovasc J Afr. 2019 Sep/Oct 23; 30(5):279-284.
    View in: PubMed
    Score: 0,599
  14. Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia. Cardiovasc Drugs Ther. 2019 02; 33(1):69-76.
    View in: PubMed
    Score: 0,575
  15. Familial hypercholesterolemia treatments: Guidelines and new therapies. Atherosclerosis. 2018 10; 277:483-492.
    View in: PubMed
    Score: 0,561
  16. Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study. JAMA Cardiol. 2017 06 01; 2(6):598-607.
    View in: PubMed
    Score: 0,512
  17. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. Lancet Diabetes Endocrinol. 2017 04; 5(4):280-290.
    View in: PubMed
    Score: 0,502
  18. Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia. J Clin Lipidol. 2016 Jul-Aug; 10(4):860-869.
    View in: PubMed
    Score: 0,471
  19. Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. Lancet Diabetes Endocrinol. 2016 05; 4(5):403-10.
    View in: PubMed
    Score: 0,467
  20. Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future. Curr Cardiol Rep. 2015 Nov; 17(11):104.
    View in: PubMed
    Score: 0,459
  21. Anacetrapib in familial hypercholesterolaemia: pros and cons. Lancet. 2015 May 30; 385(9983):2124-6.
    View in: PubMed
    Score: 0,438
  22. New therapies for reducing low-density lipoprotein cholesterol. Endocrinol Metab Clin North Am. 2014 Dec; 43(4):1007-33.
    View in: PubMed
    Score: 0,430
  23. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Jan 24; 385(9965):331-40.
    View in: PubMed
    Score: 0,425
  24. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Jan 24; 385(9965):341-50.
    View in: PubMed
    Score: 0,425
  25. Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9. Annu Rev Med. 2014; 65:417-31.
    View in: PubMed
    Score: 0,404
  26. Targeting LDL: is lower better and is it safe? Best Pract Res Clin Endocrinol Metab. 2014 Jun; 28(3):309-24.
    View in: PubMed
    Score: 0,400
  27. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012 Aug; 223(2):262-8.
    View in: PubMed
    Score: 0,355
  28. CEPHEUS SA: a South African survey on the undertreatment of hypercholesterolaemia. Cardiovasc J Afr. 2011 Sep-Oct; 22(5):234-40.
    View in: PubMed
    Score: 0,345
  29. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010 Mar 20; 375(9719):998-1006.
    View in: PubMed
    Score: 0,311
  30. A multicentre, open-label, observational local study to evaluate the low-density lipoprotein cholesterol-lowering effect of ezetimibe as prescribed in daily routine practice in the South African population. Cardiovasc J Afr. 2007 Sep-Oct; 18(5):325-9.
    View in: PubMed
    Score: 0,260
  31. Homozygous Familial Hypercholesterolemia Treatment: New Developments. Curr Atheroscler Rep. 2025 Jan 03; 27(1):22.
    View in: PubMed
    Score: 0,217
  32. Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy. Eur Heart J. 2024 Jul 12; 45(27):2422-2434.
    View in: PubMed
    Score: 0,210
  33. The South African Lipid Guidelines: is there a need for an update? Cardiovasc J S Afr. 2004 Mar-Apr; 15(2):53-4.
    View in: PubMed
    Score: 0,204
  34. Estimating potential cardiovascular health benefits of improved population level control of LDL cholesterol through a twice-yearly siRNA-based approach: A simulation study of a health-system level intervention. Atherosclerosis. 2024 Apr; 391:117472.
    View in: PubMed
    Score: 0,204
  35. Safety and Tolerability of Inclisiran for?Treatment of Hypercholesterolemia in?7 Clinical Trials. J Am Coll Cardiol. 2023 12 12; 82(24):2251-2261.
    View in: PubMed
    Score: 0,201
  36. Inclisiran in patients with prior myocardial infarction: A post hoc pooled analysis of the ORION-10 and ORION-11 Phase 3 randomised trials. Atherosclerosis. 2023 12; 386:117354.
    View in: PubMed
    Score: 0,199
  37. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J. 2023 Jul 01; 44(25):2277-2291.
    View in: PubMed
    Score: 0,195
  38. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J. 2023 01 07; 44(2):129-138.
    View in: PubMed
    Score: 0,189
  39. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Eur Heart J. 2022 12 21; 43(48):5047-5057.
    View in: PubMed
    Score: 0,188
  40. Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT. Lancet Diabetes Endocrinol. 2022 10; 10(10):732-740.
    View in: PubMed
    Score: 0,184
  41. Monkeypox is a global public health emergency: The role of repurposing cholesterol lowering drugs not to be forgotten. J Clin Lipidol. 2022 Sep-Oct; 16(5):757-758.
    View in: PubMed
    Score: 0,184
  42. Cognitive function with evolocumab in pediatric heterozygous familial hypercholesterolemia. J Clin Lipidol. 2022 Sep-Oct; 16(5):676-684.
    View in: PubMed
    Score: 0,183
  43. Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials. J Clin Lipidol. 2022 Jul-Aug; 16(4):538-543.
    View in: PubMed
    Score: 0,181
  44. A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia. Atherosclerosis. 2021 05; 325:46-56.
    View in: PubMed
    Score: 0,168
  45. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia. Atherosclerosis. 2000 Jun; 150(2):421-8.
    View in: PubMed
    Score: 0,158
  46. Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study. Circulation. 2020 06 02; 141(22):1829-1831.
    View in: PubMed
    Score: 0,158
  47. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020 04 16; 382(16):1507-1519.
    View in: PubMed
    Score: 0,155
  48. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020 04 16; 382(16):1520-1530.
    View in: PubMed
    Score: 0,155
  49. Efficacy of vitamin E compared with either simvastatin or atorvastatin in preventing the progression of atherosclerosis in homozygous familial hypercholesterolemia. Am J Cardiol. 1999 Dec 01; 84(11):1344-6, A7.
    View in: PubMed
    Score: 0,152
  50. Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia. J Am Coll Cardiol. 2019 10 29; 74(17):2132-2146.
    View in: PubMed
    Score: 0,151
  51. Familial hypercholesterolaemia workshop for leveraging point-of-care testing and personalised medicine in association with the Lipid and Atherosclerosis Society of Southern Africa. Cardiovasc J Afr. 2019 Sep/Oct; 30(5):297-304.
    View in: PubMed
    Score: 0,150
  52. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis. 2018 10; 277:234-255.
    View in: PubMed
    Score: 0,140
  53. Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. Eur Heart J. 2018 04 07; 39(14):1162-1168.
    View in: PubMed
    Score: 0,136
  54. Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab. Arterioscler Thromb Vasc Biol. 2018 03; 38(3):592-598.
    View in: PubMed
    Score: 0,133
  55. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis. Eur J Prev Cardiol. 2017 11; 24(17):1843-1850.
    View in: PubMed
    Score: 0,131
  56. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher. Cardiovasc Drugs Ther. 2016 Oct; 30(5):473-483.
    View in: PubMed
    Score: 0,122
  57. Effect of Alirocumab on Lipoprotein(a) Over =1.5 Years (from the Phase 3 ODYSSEY Program). Am J Cardiol. 2017 Jan 01; 119(1):40-46.
    View in: PubMed
    Score: 0,122
  58. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report. Arterioscler Thromb Vasc Biol. 2016 08; 36(8):1647-50.
    View in: PubMed
    Score: 0,118
  59. Phenotype diversity among patients with homozygous familial hypercholesterolemia: A cohort study. Atherosclerosis. 2016 May; 248:238-44.
    View in: PubMed
    Score: 0,118
  60. Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council. Arterioscler Thromb Vasc Biol. 2015 Nov; 35(11):2269-80.
    View in: PubMed
    Score: 0,114
  61. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16; 372(16):1489-99.
    View in: PubMed
    Score: 0,110
  62. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16; 372(16):1500-9.
    View in: PubMed
    Score: 0,110
  63. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler Thromb Vasc Biol. 2015 Mar; 35(3):689-99.
    View in: PubMed
    Score: 0,109
  64. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Eur J Prev Cardiol. 2015 Jul; 22(7):849-54.
    View in: PubMed
    Score: 0,103
  65. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur Heart J. 2014 Sep 01; 35(33):2249-59.
    View in: PubMed
    Score: 0,102
  66. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012 Nov 13; 126(20):2408-17.
    View in: PubMed
    Score: 0,093
  67. Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. J Pediatr. 2010 Feb; 156(2):231-6.e1-3.
    View in: PubMed
    Score: 0,076
  68. Drugs for dyslipidaemia: the legacy effect of the Scandinavian Simvastatin Survival Study (4S). Lancet. 2024 Dec 14; 404(10470):2462-2475.
    View in: PubMed
    Score: 0,054
  69. High-dose atorvastatin therapy is required for significant improvement of endothelial function in heterozygous familial hypercholesterolaemic patients. Cardiovasc J S Afr. 2004 Mar-Apr; 15(2):70-5.
    View in: PubMed
    Score: 0,051
  70. Lomitapide and Mipomersen-Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis. Curr Atheroscler Rep. 2019 11 19; 21(12):48.
    View in: PubMed
    Score: 0,038
  71. Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies. Clin Cardiol. 2018 Oct; 41(10):1328-1335.
    View in: PubMed
    Score: 0,035
  72. Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia. Atherosclerosis. 1997 Dec; 135(2):249-56.
    View in: PubMed
    Score: 0,033
  73. Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations. J Am Coll Cardiol. 2017 Aug 29; 70(9):1162-1170.
    View in: PubMed
    Score: 0,033
  74. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017 Aug 21; 38(32):2459-2472.
    View in: PubMed
    Score: 0,032
  75. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014 Aug 21; 35(32):2146-57.
    View in: PubMed
    Score: 0,026
  76. Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. J Clin Lipidol. 2014 Mar-Apr; 8(2):148-72.
    View in: PubMed
    Score: 0,025
  77. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int J Cardiol. 2014 Feb 15; 171(3):309-25.
    View in: PubMed
    Score: 0,025
  78. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013 Dec; 34(45):3478-90a.
    View in: PubMed
    Score: 0,025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.